Oragenics, Inc. Notifies President of Non-Renewal of Employment Agreement

Oragenics, Inc. (NYSE: OGEN) announced in a recent Form 8-K filing to the Securities and Exchange Commission that it has decided not to renew the Employment Agreement of its President, J. Michael Redmond. The Employment Agreement, dated December 28, 2023, had an initial term of one year.

As per the agreement, the initial term would automatically renew for an additional year unless either party provided a 30-day notice of non-renewal before the expiration of the initial term. Following the Company’s notice of non-renewal, Executive J. Michael Redmond’s employment under the Agreement will cease upon the expiration of the initial term. Certain provisions of the Agreement will continue to be valid even after its expiration, as stipulated in the terms of the contract.

The filing also included information regarding financial statements and exhibits, listing an Interactive Data File as Exhibit 104 that is embedded in the cover page formatted in Inline XBRL.

The Form 8-K filing was signed off by Janet Huffman, the Chief Financial Officer of Oragenics, Inc., on November 29, 2024. This move marks a strategic decision by Oragenics regarding its executive leadership and underscores the company’s commitment to effective governance and operational management.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Oragenics’s 8K filing here.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.